Preliminary
Programme
Preliminary
Programme
Thursday, 17 September 2026
Attendance is free of charge — we warmly invite you to join us.
Thursday, 17 September 2026
Attendance is free of charge —
we warmly invite you to join us.
Arrival, Lunch, Check-In
Opening of Day 1
Keynote Lecture
Georg Schett, University Hospital Erlangen, Erlangen, Germany
“Lupus in Remission – A New Immune Reality?”
Georg Schett, University Hospital Erlangen, Erlangen, Germany
“Lupus in Remission – A New Immune Reality?”
Short break
Session I: What Have We Learned So Far – T Cell Concepts in Autoimmunity
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
“Resetting the System – Autologous Stem Cell Transplantation Revisited”
Tobias Alexander, Charité-Universitätsmedizin Berlin, Berlin, Germany
“Bispecific T Cell Engagers – Bridging Specificity and Safety”
Huji Xu, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
“Allo in One: Allogeneic CAR T and NK Cells for Treatment-Refractory Autoimmunity”
Harald Prüß, Charité – Universitätsmedizin Berlin, Berlin, Germany
“From Blunt Force to Precision: CAAR T Cells in Autoimmune Disease”
Chairs:
Georg Schett, University Hospital Erlangen, Erlangen, Germany
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
What Have We Learned So Far – T Cell Concepts in Autoimmunity
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
“Resetting the System – Autologous Stem Cell Transplantation Revisited”
Tobias Alexander, Charité-Universitätsmedizin Berlin, Berlin, Germany
“Bispecific T Cell Engagers – Bridging Specificity and Safety”
Huji Xu, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
“Allo in One: Allogeneic CAR T and NK Cells for Treatment-Refractory Autoimmunity”
Harald Prüß, Charité – Universitätsmedizin Berlin, Berlin, Germany
“From Blunt Force to Precision: CAAR T Cells in Autoimmune Disease”
Chairs:
Georg Schett, University Hospital Erlangen, Erlangen, Germany
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
Short break
Industry I: Cabaletta
“Resetting the Immune System: Insights into B-Cell Depletion After CD19-CAR T Therapy”
Cabaletta
“Resetting the Immune System: Insights into B-Cell Depletion After CD19-CAR T Therapy”
Industry II: BMS
“Current and Future Potential of CAR-T Cell Therapies in the Autoimmune Space”
BMS
“Current and Future Potential of CAR-T Cell Therapies in the Autoimmune Space”
Short break
Session II: Autoimmunity Reimagined: Early Clinical Experiences with T Cell Therapy
Aiden Haghikia, Hannover Medical School, Hannover, Germany
“Translating CAR T Cell Therapy into Neuromuscular Diseases”
Everett H Meyer, Stanford University, Stanford, CA, United States
“Regulatory T Cell Therapy in Action: Clinical Insights from GvHD to Autoimmunity”
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
“Hit Hard, Hit Early: CAR T Cell Therapy in Children with Autoimmune Disorders”
Jeffrey Dunn, Stanford University, Stanford, CA, United States
“Lessons from MS – Window of Opportunity for T Cell Interventions”
Chairs:
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Sven Meuth, University of Münster, Münster, Germany
Autoimmunity Reimagined: Early Clinical Experiences with T Cell Therapy
Aiden Haghikia, Hannover Medical School, Hannover, Germany
“Translating CAR T Cell Therapy into Neuromuscular Diseases”
Everett H Meyer, Stanford University, Stanford, CA, United States
“Regulatory T Cell Therapy in Action: Clinical Insights from GvHD to Autoimmunity”
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
“Hit Hard, Hit Early: CAR T Cell Therapy in Children with Autoimmune Disorders”
Jeffrey Dunn, Stanford University, Stanford, CA, United States
“Lessons from MS – Window of Opportunity for T Cell Interventions”
Chairs:
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Sven Meuth, University of Münster, Münster, Germany
Shuttle service with busses to Hotel Motel One Magdeburg and
Basta. – Wein, Events, Pizza (location for the dinner)
Dinner at Basta. – Wein, Events, Pizza
(Halberstädter Str. 51-53, 39112 Magdeburg)
Shuttle service with busses to Hotel Motel One Magdeburg
Friday, 18 September 2026
Attendance is free of charge — we warmly invite you to join us.
Friday, 18 September 2026
Attendance is free of charge —
we warmly invite you to join us.
Shuttle service with busses to the Universitätsklinikum Magdeburg
Get Together and Coffee
Session III: Engineering & Innovation
Chiara Bonini, Ospedale San Raffaele, Milano, Italy
“Redirected Tregs as a Non-Cytotoxic Strategy to Reestablish Immune Homeostasis”
Axel Schambach, Hannover Medical School, Hannover, Germany
“Inject, Target, Reprogram: In Vivo CAR T Cells”
Michael Hudecek, University Hospital Würzburg, Würzburg, Germany
“Engineering Lessons from Oncology: Making CAR T-Cell Therapy Accessible and Effective in Autoimmunity”
Juan Manel, Hospital Clinic de Barcelona, Barcelona, Spain
“PoC Manufacturing: can academia compete with pharma?”
Chair:
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
David Simon, Charité – Universitätsmedizin Berlin, Berlin, Germany
Engineering & Innovation
Chiara Bonini, Ospedale San Raffaele, Milano, Italy
“Redirected Tregs as a Non-Cytotoxic Strategy to Reestablish Immune Homeostasis”
Axel Schambach, Hannover Medical School, Hannover, Germany
“Inject, Target, Reprogram: In Vivo CAR T Cells”
Michael Hudecek, University Hospital Würzburg, Würzburg, Germany
“Engineering Lessons from Oncology: Making CAR T-Cell Therapy Accessible and Effective in Autoimmunity”
Juan Manel, Hospital Clinic de Barcelona, Barcelona, Spain
“PoC Manufacturing: can academia compete with pharma?”
Chair:
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
David Simon, Charité – Universitätsmedizin Berlin, Berlin, Germany
Short break
Industry III: Fresenius Kabi
“Redefining Point of Care Manufacturing for CAR-T Immune Reset”
Fresenius Kabi
“Redefining Point of Care Manufacturing for CAR-T Immune Reset”
Industry IV: Astra Zeneca
“Target induced T-cell activating nanobody (TITAN): Next generation T-cell engager for autoimmune diseases”
Astra Zeneca
“Target induced T-cell activating nanobody (TITAN): Next generation T-cell engager for autoimmune diseases”
Short break
Session IV: Clinical Implementation & Risk Management
Robert Zeiser, University of Freiburg Medical Center, Freiburg, Germany
“Preclinical Models for CRS & ICANS – Lessons Learned”
Remy Dulery, Dana-Farber Cancer Institute, Boston MA, USA
“Secondary Malignancies – Myth or Real Long-Term Concern?”
Melanie Hagen, University Hospital Erlangen, Erlangen, Germany
“New indications – new toxicities?”
Raffaella Greco, Ospedale San Raffaele, Milano, Italy
“EBMT Guidelines Revisited: When, who, and how.”
Chair:
Stephan Fricke, University Hospital Magdeburg, Magdeburg, Germany
Fabian Müller, University Hospital Erlangen, Erlangen, Germany
Clinical Implementation & Risk Management
Robert Zeiser, University of Freiburg Medical Center, Freiburg, Germany
“Preclinical Models for CRS & ICANS – Lessons Learned”
Remy Dulery, Dana-Farber Cancer Institute, Boston MA, USA
“Secondary Malignancies – Myth or Real Long-Term Concern?”
Melanie Hagen, University Hospital Erlangen, Erlangen, Germany
“New indications – new toxicities?”
Raffaella Greco, Ospedale San Raffaele, Milano, Italy
“EBMT Guidelines Revisited: When, who, and how.”
Chair:
Stephan Fricke, University Hospital Magdeburg, Magdeburg, Germany
Fabian Müller, University Hospital Erlangen, Erlangen, Germany
Lunch
Final Panel Discussion: How Far Can T Cells Go in Autoimmunity?
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
Jeffrey Dunn, Stanford University, Stanford, CA, United States
Huji Xu, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
Moderation:
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
How Far Can T Cells Go in Autoimmunity?
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
Jeffrey Dunn, Stanford University, Stanford, CA, United States
Huji Xu, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
Moderation:
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
